CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of “Hold” from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has been assigned an average rating of “Hold” from the eighteen research firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $64.5294.

A number of brokerages recently weighed in on CRSP. Chardan Capital raised their price target on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research note on Saturday, February 14th. Bank of America cut their price objective on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Thursday, January 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Citigroup restated a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, February 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY commercial momentum — Patient starts for CASGEVY nearly tripled year‑over‑year and CRISPR plans a H1 2026 pediatric label filing, supporting revenue growth potential and commercial credibility. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Positive Sentiment: Clinical validation for CTX310 — Early CTX310 data were published in the New England Journal of Medicine and the program is moving into Phase 1b, adding clinical proof‑of‑concept for a key cardiovascular asset. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Neutral Sentiment: $550M convertible note — The company raised US$550M via 1.7308% convertible senior notes due 2031, which materially boosts cash runway to fund commercialization and trials but introduces potential future dilution if converted. How Investors May Respond To CRISPR Therapeutics (CRSP) $550 Million Convertible Note Boost To Cash Reserves
• Neutral Sentiment: Analyst stance — Piper Sandler reaffirmed an Overweight rating, which is supportive but not uncommon after mixed news; keep an eye on analyst commentary around upcoming data readouts. Piper Sandler Reaffirms Overweight Rating for CRISPR Therapeutics (NASDAQ:CRSP)
• Neutral Sentiment: Short‑interest data appear inconsistent — Recent reports show zero shares and NaN changes, suggesting a data error or reporting lag; this is not currently providing a clear signal on positioning. (Data entries: 3/19–3/20)
• Negative Sentiment: Pipeline uncertainty and timing risk — Coverage notes that while CASGEVY sales are encouraging, several pipeline candidates are early‑stage and investors will wait for additional clinical readouts over the next 12 months before revising convictions. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Negative Sentiment: Recent share weakness — Multiple market summaries reported multi‑day declines (mid‑ to late‑March), reflecting investor caution despite positive commercial and financing headlines; short‑term price action likely driven by sentiment and upcoming catalysts. CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market Zacks: CRSP Registers a Bigger Fall Than the Market

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $46.24 on Monday. The firm has a fifty day moving average of $53.26 and a 200 day moving average of $57.12. The firm has a market cap of $4.44 billion, a PE ratio of -7.09 and a beta of 1.71. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The company had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business’s revenue for the quarter was down 97.8% on a year-over-year basis. During the same period in the previous year, the business earned ($1.01) earnings per share. On average, equities analysts predict that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 3,450 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $166,497.00. Following the completion of the sale, the general counsel owned 91,240 shares of the company’s stock, valued at $4,403,242.40. This represents a 3.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Naimish Patel sold 3,150 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $152,019.00. Following the completion of the sale, the insider owned 13,143 shares of the company’s stock, valued at $634,281.18. This trade represents a 19.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 128,626 shares of company stock worth $7,126,807. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Large investors have recently bought and sold shares of the business. Fund Advisors of America Inc FL acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $398,000. Virtu Financial LLC purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $862,000. Mcguire Capital Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $25,000. Axxcess Wealth Management LLC increased its holdings in shares of CRISPR Therapeutics by 6.2% in the fourth quarter. Axxcess Wealth Management LLC now owns 13,022 shares of the company’s stock valued at $683,000 after purchasing an additional 764 shares during the last quarter. Finally, Corient Private Wealth LLC lifted its position in CRISPR Therapeutics by 5.7% during the fourth quarter. Corient Private Wealth LLC now owns 8,566 shares of the company’s stock worth $449,000 after buying an additional 460 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.